01/28/2015 - 5:34pm

"During one of the sessions at the 2008 NACDS Regional Chain Conference, we projected onto the video screen some images of advertisements that NACDS was beginning to use in the Washington, D.C. area. Looking back, one of the things that I remember most was the boldness and strategic focus of the tagline: 'Pharmacies. The face of neighborhood healthcare.' With the 2015 edition of this meeting just days away, it is striking how far we have come!" writes NACDS president and CEO Steve Anderson in his latest blog post. 

01/28/2015 - 2:53pm

The House Energy and Commerce Committee on Tuesday released a discussion document in the 21st Century Cures initiative.

01/28/2015 - 1:11pm

Bipartisan legislation has been introduced in the U.S. House of Representatives that would formally designate pharmacists as healthcare providers under Medicare Part B.

01/27/2015 - 12:07pm

Symplmed Pharmaceuticals announced that the Food and Drug Administration approved Prestalia (perindopril arginine and amlodipine) tablets to treat hypertension. 

01/27/2015 - 12:01pm

Rep. Jason Chaffetz, R-Utah, last week introduced a bill that would extend to new combination drugs containing molecules already approved by the Food and Drug Administration the same five-year market exclusivity as a drug product containing an entirely new set of active ingredients.

01/27/2015 - 11:11am

Health and Human Services Secretary Sylvia Burwell announced goals and a timeline to move the Medicare program toward paying providers based on the quality of care they give patients.

 

01/27/2015 - 11:09am

Teva Pharmaceutical Industries announced that the Food and Drug Administration approved the company’s first generic Nexium delayed-release tablets in the United States.

01/27/2015 - 10:34am

The Food and Drug Administration on Monday announced approval for the first generic version of Nexium (esomeprazole magnesium delayed-release capsules), which are used to treat gastroesophageal reflux disease in adults and children ages 1 year and older.

01/26/2015 - 3:12pm

The Food and Drug Administration last week announced approval for Bexsero, a vaccine intended to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in individuals 10 years through 25 years of age.